Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Retained Earnings (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Retained Earnings for 4 consecutive years, with -$772.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 102044.59% to -$772.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$772.7 million, a 102044.59% decrease, with the full-year FY2024 number at $324000.0, up 200.0% from a year prior.
  • Retained Earnings was -$772.7 million for Q3 2025 at Century Therapeutics, down from -$738.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $758000.0 in Q3 2024 to a low of -$772.7 million in Q3 2025.
  • A 4-year average of -$280.5 million and a median of -$2.5 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: skyrocketed 200.0% in 2024, then crashed 292753.53% in 2025.
  • Century Therapeutics' Retained Earnings stood at -$2.5 million in 2022, then soared by 104.39% to $108000.0 in 2023, then surged by 200.0% to $324000.0 in 2024, then tumbled by 238600.0% to -$772.7 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Retained Earnings are -$772.7 million (Q3 2025), -$738.3 million (Q2 2025), and -$705.8 million (Q1 2025).